OSR Health, Inc. filed a Form 8-K on October 28, 2026, disclosing that the Nasdaq Hearings Panel denied the company's request for continued listing and determined to delist its securities from Nasdaq.

Key Highlights

  • Panel decision received October 23, 2026: The Nasdaq Hearings Panel issued a written decision denying OSR Health's request for continued listing.
  • Delisting determined: The Panel determined to delist the company's securities from The Nasdaq Stock Market LLC.
  • Trading suspended August 26, 2026: According to the filing, trading in the company's common stock and warrants on Nasdaq was suspended effective at the open of trading on August 26, 2026.
  • Non-compliance trigger: The suspension was due to the company's non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
  • OTC trading continues: The company's securities continue to be quoted on the over-the-counter market under the symbols "OSRH" and "OSRHW."
  • Options under evaluation: The filing states that "The Company is evaluating its options."

Nasdaq Hearings Panel Denies OSR Health's Continued Listing Request

According to the Form 8-K filed with the SEC on October 28, 2026, OSR Health, Inc. (NASDAQ:OSRH) disclosed that its common stock and warrants had their Nasdaq trading suspended effective at the open of trading on August 26, 2026. The filing states that the suspension arose from the company's non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Following the suspension, the company requested a hearing before the Nasdaq Hearings Panel.

The filing discloses that on October 23, 2026, the company received a written decision from the Panel denying OSR Health's request for continued listing and determining to delist the company's securities from Nasdaq. The company's common stock trades under the symbol "OSRH" and its redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share, trade under the symbol "OSRHW," both now quoted on the over-the-counter market. The company stated it "is evaluating its options" following the Panel's determination.

Separately, the filing notes that on October 28, 2026, the company issued a press release providing an update to shareholders following the Panel's decision. That press release was furnished as Exhibit 99.1 to the Current Report. The filing was signed by Kuk Hyoun Hwang, Chief Executive Officer, on October 28, 2026. OSR Health is incorporated in Delaware and is headquartered at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004.

What Was Disclosed

OSR Health disclosed that the Nasdaq Hearings Panel denied its continued listing request and determined to delist its securities, following a trading suspension that began August 26, 2026, due to non-compliance with Nasdaq's minimum bid price rule. The company's securities continue trading on the over-the-counter market.